Which class of medications can induce remission in inflammatory bowel disease by neutralizing TNF-alpha?

• A. Anti-TNF biologics
• B. JAK inhibitors
• C. Integrin antagonists
• D. Anti-IL-6 therapy

Answer: (A)

The key idea is that reducing TNF-alpha activity can quell the intestinal inflammation seen in IBD enough to bring about remission. TNF-alpha is a central pro-inflammatory cytokine that drives immune cell recruitment, cytokine production, and tissue damage in the gut. Anti-TNF biologics are monoclonal antibodies or receptor fusion proteins that bind TNF-alpha, blocking its interaction with TNF receptors on immune and gut‐lining cells. This interrupts the inflammatory signaling cascade, lowers production of other inflammatory mediators, reduces leukocyte influx, and promotes healing of the mucosa. Because of this direct neutralization of a major inflammatory driver, these therapies can induce remission in moderate-to-severe Crohn’s disease and ulcerative colitis, including fistulizing disease or cases where conventional therapies fail. Examples include infliximab, adalimumab, certolizumab, and golimumab, given IV or subcutaneously depending on the agent. Other options act through different pathways—JAK inhibitors disrupt intracellular signaling, integrin antagonists prevent lymphocyte trafficking to the gut, and anti-IL-6 therapies target a different cytokine—so they do not neutralize TNF-alpha.